Results 281 to 290 of about 142,317 (291)

Polymorphic Mucocutaneous Eruption and Septic Shock in a 75‐Year‐Old Man

JEADV Clinical Practice, EarlyView.
Sweta Subhadarshani, Brad R. Woodie, Kerith E. Spicknall   +2 more
wiley   +1 more source

Model‐Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Model‐informed drug development (MIDD) has been increasingly applied to guide decision‐making, ameliorate efficiency, and enhance the likelihood of successful trials. The development of ligelizumab, a humanized anti‐IgE monoclonal antibody, in chronic spontaneous urticaria (CSU) illustrated how MIDD can be applied to support central aspects of
Andrzej Bienczak, Aurelie Gautier, Eva Hua, Yan Ji, Emil Scosyrev, Serge Smeets, Thomas Severin, Anton Drollmann, Manmath Patekar, Marina Savelieva   +9 more
wiley   +1 more source

Response to Comment on Noso et al. Rapid and Slow Progressors Toward β-Cell Depletion and Their Predictors in Type 1 Diabetes: Prospective Longitudinal Study in Japanese Type 1 Diabetes (TIDE-J). Diabetes Care 2025;48:1438-1445. [PDF]

Diabetes Care
Noso S, Ikegami H, Japanese Type 1 Diabetes Database Study (TIDE-J) .   +2 more
europepmc   +1 more source

Nipocalimab Dose Selection in Generalized Myasthenia Gravis

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
Model‐Informed Nipocalimab Dose Selection for Generalized Myasthenia Gravis. ABSTRACT Nipocalimab is a fully human immunoglobulin G (IgG)1 monoclonal antibody (mAb) designed to selectively block the IgG binding site of neonatal fragment crystallizable receptor (FcRn) to inhibit IgG recycling and decrease circulating IgG, including pathogenic IgG ...
Belén Valenzuela, Martine Neyens, Yaowei Zhu, Sindhu Ramchandren, Anne‐Gaëlle Dosne, Jocelyn H. Leu, Ruben Faelens, Leona E. Ling, Juan‐José Pérez‐Ruixo   +8 more
wiley   +1 more source

Immunomodulation of behavior impairment via spleen-specific targeting lipid nanoparticles in a MeCP2 transgenic mouse model. [PDF]

Sci Rep
Zhang S, Li Y, Yang B, Teymur A, Atrooz F, Majd S, Mohan C, Salim S, Wu T.   +8 more
europepmc   +1 more source

AChR Autoantibody Pathogenic Properties Are Heterogeneously Distributed and Undergo Temporal Changes Among Patients With Myasthenia Gravis. [PDF]

Neurol Neuroimmunol Neuroinflamm
Khani-Habibabadi F, Roy B, Pham MC, Obaid AH, Filipek B, Nowak RJ, O'Connor KC.   +6 more
europepmc   +1 more source

Autoantibody spark response predicts treatment outcome in patients receiving chemoradiation followed by durvalumab therapy. [PDF]

Sci Rep
Mori T, Kitagawa M, Hasegawa T, Someya M, Tsuchiya T, Gocho T, Honjo T, Date M, Morii M, Miyamoto A, Futami J.   +10 more
europepmc   +1 more source

Atypical Presentation of Seronegative Autoimmune Encephalitis as Refractory Status Epilepticus: A Case Report. [PDF]

Am J Case Rep
Alalawi B, Beitar F, Alalawi S, Alhariri H.   +3 more
europepmc   +1 more source

Crosstalk Between Keratinocytes and T Cells in Ulcerative Oral Mucosal Diseases: Mechanisms of Epithelial Dysfunction and Therapeutic Perspectives. [PDF]

J Inflamm Res
Hao Y, Yuan Y, Yu Y, Liu C, Wang Z, Li Y, Chen Q.   +6 more
europepmc   +1 more source

Autoantibody origins in lupus and in relapse post CAR-T therapy

Grenov A, Yoon J, Snell DM, Mikolajczak A, Wang H, Gürel E, Ronchel AR, Yegen G, Lee L, Esen BA, Rahman A, Maciocia P, Vinuesa CG.   +12 more
europepmc   +1 more source